Eliquis™(apixaban) is the culmination of an intense medicinal chemistry effort to identify a
highly optimized inhibitor of coagulation factor Xa (FXa). We sought to identify a safe and …

Introduction Thromboembolic events represent the final common mechanism in the
pathogenesis of the most lethal vascular diseases in the developed countries (including …

For the last half-century, despite its many limitations warfarin has been the mainstay of
treatment for patients with venous and arterial thromboembolic disease. During the past …

From the 1940s through 2010, warfarin (Coumadin, Bristol-Myers Squibb) was the only oral
anticoagulant on the market in the US for the treatment and prevention of thromboembolic …

Apixaban, an oral direct factor Xa inhibitor, is currently in late stage clinical development for
the prevention and treatment of thromboembolic diseases. In comparison with current …

Currently available anticoagulants include heparin, low-molecular-weight heparin,
fondaparinux and warfarin. Despite advances, currently available agents have limitations …

Cardiovascular diseases are still the most important cause of morbidity and mortality
worldwide and anti-thrombotic treatment is widely used as a result. The currently used drugs …

Apixaban (BMS-562247-01) is a compound being investigated as an anticoagulant.
Apixaban molecule is developed in a joint venture by Pfizer and Bristol-Myers Squibb …

Abstract Apixaban (BMS-562247; 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)
phenyl)-4, 5, 6, 7-tetrahydro-1 H-pyrazolo [3, 4-c] pyridine-3-carboxamide), a direct inhibitor …

Background: Apixaban is an oral, direct and highly selective factor Xa (FXa) inhibitor in late‐
stage clinical development for the prevention and treatment of thromboembolic diseases …